RFM
REGN icon

Royal Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Royal Fund Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1
Closed – – 477
2020
Q1 		$0 Hold
1
– – ﹤0.01% 699
2019
Q4 		$0 Hold
1
– – ﹤0.01% 685
2019
Q3 		$0 Hold
1
– – ﹤0.01% 646
2019
Q2 		$0 Hold
1
– – ﹤0.01% 636
2019
Q1 		$0 Hold
1
– – ﹤0.01% 654
2018
Q4 		$0 Hold
1
– – ﹤0.01% 635
2018
Q3 		$0 Hold
1
– – ﹤0.01% 627
2018
Q2 		$0 Hold
1
– – ﹤0.01% 620
2018
Q1 		$0 Hold
1
– – ﹤0.01% 661
2017
Q4 		$0 Hold
1
– – ﹤0.01% 684
2017
Q3 		$0 Hold
1
– – ﹤0.01% 509
2017
Q2 		$0 Hold
1
– – ﹤0.01% 501
2017
Q1 		$0 Hold
1
– – ﹤0.01% 461
2016
Q4 		$0 Buy
+1
New +$380 ﹤0.01% 408

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Royal Fund Management's REGN Position: Q2 2020 in Review

Royal Fund Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2020, closing a stake of 1 share.

Royal Fund Management first reported a position in REGN in Q4 2016 and held it in 14 quarters. The position peaked at $0 in Q1 2020. 932 funds tracked by Wall St. Rank hold REGN as of Q2 2020.

  • Royal Fund Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Royal Fund Management sold 1 Regeneron Pharmaceuticals share in Q2 2020.
  • Royal Fund Management first reported a position in Regeneron Pharmaceuticals in Q4 2016 and held it in 14 quarters.
  • Royal Fund Management's Regeneron Pharmaceuticals position peaked at $0 in Q1 2020.
  • 932 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2020.

Based on Royal Fund Management's 13F filing for Q2 2020, filed 6 Aug 2020.